Bender Robert & Associates’s Idexx Laboratories IDXX Stock Holding History

Bender Robert & Associates’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-397	Closed	-$214K	–	61
2024 Q1	$214K	Sell	397 -25	-6%	-$13.7K	0.05%	43
2023 Q4	$234K	Sell	422 -38	-8%	-$17.8K	0.06%	44
2023 Q3	$201K	Hold	460	–	–	0.06%	45
2023 Q2	$231K	Sell	460 -5	-1%	-$2.4K	0.06%	44
2023 Q1	$233K	Buy	+465	New	+$223K	0.07%	49
2022 Q2	–	Sell	-490	Closed	-$268K	–	56
2022 Q1	$268K	Sell	490 -15	-3%	-$7.89K	0.08%	45
2021 Q4	$314K	Hold	505	–	–	0.09%	44
2021 Q3	$314K	Buy	+505	New	+$339K	0.09%	46
2021 Q2	–	Sell	-510	Closed	-$250K	–	50
2021 Q1	$250K	Buy	+510	New	+$256K	0.08%	50

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bender Robert & Associates's IDXX Position: Q2 2024 in Review

Bender Robert & Associates sold out of Idexx Laboratories (IDXX) in Q2 2024, closing a stake of 397 shares — an estimated $214K sold.

Bender Robert & Associates first reported a position in IDXX in Q1 2021 and held it in 9 quarters. The position peaked at $314K in Q4 2021. 1,110 funds tracked by Wall St. Rank hold IDXX as of Q2 2024.

Bender Robert & Associates reported no remaining Idexx Laboratories position as of Q2 2024 after selling out during the quarter.
Bender Robert & Associates sold 397 Idexx Laboratories shares in Q2 2024, an estimated $214K.
Bender Robert & Associates first reported a position in Idexx Laboratories in Q1 2021 and held it in 9 quarters.
Bender Robert & Associates's Idexx Laboratories position peaked at $314K in Q4 2021.
1,110 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2024.

Based on Bender Robert & Associates's 13F filing for Q2 2024, filed 30 Jul 2024.